Undisclosed TiNA-based Immunotherapy

About AilseBio

AilseBio is an early-stage biotech leveraging its proprietary TiNA Discovery platform to identify novel, therapy-induced antigens for next-generation immunotherapies. Operating from London and founded in 2021, the company is positioned in the high-potential oncology vaccine and immunotherapy space. As a private, pre-clinical stage company, it is likely in a seed or Series A funding phase, building its foundational science and pipeline. Its success hinges on validating its novel antigen discovery approach and translating it into effective clinical candidates.

Therapeutic Areas

Other Oncology (likely solid tumors) Drugs